enGene Therapeutics (ENGN) Guggenheim’s Inaugural Healthcare Innovation Conference summary

Lead asset and market opportunity

• Detalimogene is a non-viral gene therapy for non-muscle invasive bladder cancer, currently in a pivotal program with a clear regulatory path and significant market growth potential from $2 billion to $20 billion.

• The therapy addresses a high unmet need, especially in the post-BCG setting, where current and new agents are insufficient.

• Detalimogene is positioned as a first-choice therapy due to demonstrated efficacy, best-in-class tolerability, and convenience for both patients and physicians.

• Administration is simpler than BCG, requiring fewer instillations and no special handling, making it suitable for community urology practices.

• The product's profile aligns with the needs of community urologists, who manage most NMIBC patients and value efficacy, tolerability, and convenience.

Clinical data and protocol amendments

• Preliminary LEGEND study data in 21 patients showed a 71% complete response rate and a favorable safety profile, with only mild, reversible adverse events and no discontinuations due to side effects.

• Protocol amendments include allowing re-induction for certain recurrences, re-resection of T1 tumors before study entry, and more objective response assessments, aligning with standard clinical practice.

• These changes are expected to improve patient retention, response rates, and enrollment, and are already being implemented without delays.

• The amendments have been submitted to the FDA, with no anticipated regulatory issues as drug and dosing remain unchanged.

• Future data updates will include patients treated under the amended protocol, with full enrollment and another preliminary data update expected next year.

Regulatory and commercial outlook

• Filing for regulatory approval is targeted for mid-2026, with ongoing enrollment and protocol amendments expected to support this timeline.

• Additional study cohorts include BCG-naive, BCG-experienced, and BCG-refractory papillary-only patients, addressing broader clinical needs and potential guideline inclusion.

• The BCG-naive cohort is enrolling, aiming to address shortages and provide a more convenient alternative for elderly patients.

• Commercial strategy in the U.S. involves a direct sales approach with a manageable team, while ex-U.S. markets may involve partnerships based on cost-benefit analysis.

• Global regulatory and clinical strategies are being developed in parallel to U.S. efforts.